GLP-1 side effects follow a predictable pattern: heaviest in the first two weeks, returning at each dose escalation, then easing through maintenance. The most common are nausea, fatigue, appetite suppression, and GI symptoms — all dose-dependent and self-limiting in most users.[¹][²] This page covers what to expect week by week, and the symptoms that warrant a call to your doctor.
Weeks 1–4 — starting dose
Typical starting dose for semaglutide is 0.25 mg weekly; tirzepatide is 2.5 mg weekly. Symptoms users commonly report:
- Mild to moderate nausea, especially day 1–2 after the injection
- Fatigue — particularly afternoon energy dips
- Loss of appetite — most users report dramatic reduction in hunger by week 2
- Constipation
- Headaches in the first 7–10 days
Weeks 5–12 — first titration steps
Dose escalates: semaglutide to 0.5 then 1.0 mg; tirzepatide to 5.0 then 7.5 mg. Each escalation typically brings a fresh wave of GI symptoms for 5–10 days.
- Nausea returns at each step-up — usually milder than week 1 but real
- "Sulphur burps" or "egg burps" reported by ~10–15% of users at higher doses
- Continued appetite suppression
- Possible reflux or heartburn
Weeks 13–24 — approaching peak dose
Dose escalates further: semaglutide to 1.7 then 2.4 mg; tirzepatide to 10 then 12.5 then 15 mg. Most users reach their peak dose somewhere in this window.
- GI symptoms generally easier than during escalation
- Fatigue may persist or improve depending on individual
- Plateaus possible — weight loss is rarely linear
- First reports of "Ozempic face" appearance in users who lost weight fastest
Months 7–12 — maintenance phase
Most users settle into a rhythm. Side effects are typically minimal at this stage. New issues that may emerge:
- Reduced enjoyment of food — some users miss the social pleasure
- Loose skin if weight loss has been rapid
- "Ozempic face" appearance — most pronounced in users who lost weight fastest
- Plateaus that may require a Plateau Breaker reset
When to call your doctor
- Severe abdominal pain (especially if persistent) — possible pancreatitis
- Vomiting that prevents you from keeping liquids down
- Signs of dehydration — dark urine, dizziness on standing
- Vision changes
- Signs of gallbladder issues — right upper-quadrant pain, fever
What Muscle Guard tracks for you
The Personal Coach surfaces side-effect clusters before they derail your week. The Clinical Report colour-codes symptoms by severity, clustered by week — so when you do bring this to your doctor, they see the pattern in 60 seconds, not 12 weeks of guessing.
Citations
- Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. doi.org/10.1056/NEJMoa2032183
- Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. doi.org/10.1056/NEJMoa2206038
Related articles
Rybelsus and oral semaglutide: how it compares to weekly shots
Rybelsus is the daily oral GLP-1 pill. Efficacy, dosing schedule, and how to track adherence with Muscle Guard.
Mounjaro vs Ozempic vs Wegovy — the comparison
How tirzepatide (Mounjaro / Zepbound) compares to semaglutide (Wegovy / Ozempic) on efficacy, side effects, cost, and muscle preservation. Drug-by-drug, evidence-based.
GLP-1s in South Africa 2026: access, pricing, and the compounded landscape
What South Africans actually pay for Ozempic, Mounjaro, and compounded semaglutide in 2026. Medical aid coverage, pharmacy options, and tracking with ZAR pricing.
Track this with Muscle Guard
The free app that puts muscle preservation in the headline. 7-day Pro trial, no card needed.
Get the app →Muscle Guard is a self-tracking companion and coach. Not a medical device. Not medical advice. Always consult your healthcare provider for personal decisions.